Preclinical studies have also suggested that aryl hydrocarbon receptor could become another possible target of the IDO/TDO kynurenine pathway in the treatment of cancer, due to its immunosuppressive role in tumours [28]. The gene discussed is AHR; the disease is neoplasm.